SCHEMBL366177

SCHEMBL366177

COc1ccc(Cn2cc3c(n2)C(C(C)C)OCCC3=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.41
PDE1A P54750 6/20 0.37
PDE1B Q01064 6/20 0.37
PDE1C Q14123 6/20 0.37
CMA1 P23946 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 1/20 0.36
CASP3 P42574 1/20 0.36
GRM2 Q14416 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HKDC1 Q2TB90 1/20 0.35
TACR1 P25103 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837350 0.86 AADAT (0.43) AADATPDE1APDE1BPDE1CCMA1
SCHEMBL365075 0.82 AADAT (0.40) AADATPDE1APDE1BPDE1CCMA1
SCHEMBL367135 0.82 AADAT (0.41) AADATPDE1APDE1BPDE1CCMA1
SCHEMBL15182504 0.78 AADAT (0.46) AADATCMA1MEN1KMT2AGAA
SCHEMBL6837296 0.76 AADAT (0.43) AADATCMA1MEN1KMT2AGAA
SCHEMBL365074 0.74 AADAT (0.43) AADATCMA1MEN1KMT2AGAA
SCHEMBL366179 0.74 AADAT (0.41) AADATPDE1APDE1BPDE1CCMA1
SCHEMBL366615 0.73 AADAT (0.42) AADATCMA1SMN1; SMN2MEN1KMT2A
SCHEMBL365659 0.73 ALDH1A1 (0.48) AADATCMA1SMN1; SMN2MEN1KMT2A
SCHEMBL6837301 0.73 ALDH1A1 (0.48) AADATCMA1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885PDE1A 318/4885PDE1B 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.